CEBPA and acute myeloid leukemia: Furthermore, C/EBPα is inhibited post-translationally in AML cases that contain mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor (such as internal tandem duplications, ITDs; present in 30% of AML patients34).